The purpose of the study is to examine the effects of the administration of a drug called
DAR-0100A on attention and memory in persons with schizotypal personality disorder (SPD).
DAR-0100A has not been FDA approved, however in recent studies has been used to treat
cognitive deficits, meaning problems in the way you organize your thinking, in people
diagnosed with schizophrenia.
Many people who carry a diagnosis of schizotypal personality disorder have trouble with
attention and memory. Increasing the presence of a brain chemical called dopamine has been
found to help people with schizophrenia with their attention and memory problems. This study
will investigate whether the same is true for people with schizotypal personality disorder by
using DAR-0100A, a drug that has been shown to help with the cognitive deficits of people
with Parkinson's disease by increasing dopamine effects. Information collected in this
experiment may lead to a better understanding of the brain mechanisms involved in schizotypal
personality disorder and improve treatments for the psychological problems associated with
this condition.
Phase:
Phase 2
Details
Lead Sponsor:
Antonia New
Collaborators:
National Institute of Mental Health (NIMH) New York State Psychiatric Institute